What "the menopause studies" studied
The 2026 systematic review and meta-analysis pooled seven randomized controlled trials with 608 postmenopausal women. Mean age was about 62 years, and trial durations ranged from 12 to 104 weeks. Doses varied more than most summaries admit: some trials used 5 g/day, one used 3 g/day for two years, one used 1 g/day for one year, and one used a loading phase followed by 5 g/day. Several trials paired creatine with resistance training.
One important boundary for perimenopausal readers: this evidence base is mainly postmenopausal. It should not be presented as if it directly studied the full menopause transition, and we will not do that here. That gap has its own page, creatine for perimenopause. The daily habit, if you still want one, is how to take creatine.
Muscle and strength: the strongest part of the story
In the 2026 meta-analysis, pooled lean mass favored creatine by 0.37 kg, with a 95% confidence interval from 0.05 to 0.69 kg. Leg-press one-repetition maximum favored creatine by 7.5 kg, with a 95% confidence interval from 2.2 to 12.8 kg. These are modest numbers, and that is precisely why they are believable. Small, consistent effects across trials are the signature of something real.
The pattern inside the data matters too. Benefits were evident in trials using at least 5 g/day with resistance training. Trials using 3 g/day or less without resistance training did not show measurable benefit. That is a subgroup observation from the included studies, not a personal dosing prescription, but it tells a coherent story: the dose has to be real, and the training has to be there. Creatine amplifies the work. It does not replace it.
Bone density: the null result the hype skips
Bone mineral density, or BMD, is the amount of mineral measured in a defined bone area. The 2026 meta-analysis found no overall improvement in BMD with creatine. If you have seen claims that creatine strengthens menopausal bones, this is the finding those claims are skipping.
A 2015 randomized trial followed 47 postmenopausal women assigned to creatine or placebo during a supervised resistance-training program. Thirty-three completed the 12-month analysis. Femoral-neck BMD declined in both groups, but the decline was smaller with creatine: 1.2% versus 3.9% with placebo. That is slowed loss, not a density gain, and the distinction matters.
Then came the biggest test. A 2023 two-year randomized trial enrolled 237 postmenopausal women in an exercise program, and creatine had no effect on BMD at the femoral neck, total hip, or lumbar spine compared with placebo. Two years, 237 women, no density effect. That is the state of the evidence.
Bone geometry: a separate finding, not a consolation prize
Bone geometry describes structural features such as width and resistance to bending. It is not the same as BMD, and collapsing the two is how misleading headlines are born.
In the 2015 trial, creatine increased femoral shaft subperiosteal width compared with placebo. In the 2023 trial, creatine maintained section modulus and buckling ratio better than placebo at the narrow part of the femoral neck. Those are real geometric outcomes from real trials, and they are interesting on their own terms. They do not mean the bone became denser, and they do not prove fewer fractures. Honest science holds both thoughts at once.
Fracture risk: not established yet
The trials above were not fracture-prevention trials, and no amount of favorable geometry changes that. A favorable change in a geometric measure can be biologically interesting, but it cannot be translated into "creatine prevents fractures" without direct fracture-outcome evidence. Anyone selling you that translation is out ahead of the data. We would rather tell you what is missing than sell you what is not there.
Other outcomes: the functional win nobody headlines
In the 2023 trial, the creatine group improved 80-meter walking time relative to placebo. Walking speed is a real functional measure, not a lab number. It is the kind of outcome that shows up in daily life. The trial did not find a creatine advantage for one-repetition maximum bench press or hack squat strength in the full analysis. A valid-completer subanalysis found a lean-tissue advantage, but subanalyses deserve more caution than primary outcomes, so file that one accordingly.
What this means for your routine
The best-supported practical interpretation is narrow, and narrow is good. In postmenopausal women, creatine appears most useful as an adjunct to resistance training for lean mass and strength. The evidence does not establish creatine as a treatment for low bone density or osteoporosis, and we will not soften that sentence to make it more exciting.
If you want to compare a steady dose with loading, use the creatine dose calculator and read the loading comparison. For the broader audience guide, see Creatine for Women. In your 50s? See our guide to creatine for women over 50 for the age-specific trial evidence. Ready to compare products? See the best creatine for women over 40. For product picks aimed at this stage, see creatine picks for menopause. For habit-building, see the first-month guide and timing guide. The outcome split, strength versus lean mass versus bone, is on creatine benefits for women.
If the next question is the tub, the best creatine for women starts with a 5 g micronized powder. When a seal matters more than the tub, the best creatine monohydrate is the plain pouch with a listing you can open.
The open questions, stated plainly
- Perimenopause specifically is underrepresented.
- The trials do not establish fracture prevention.
- Long-term evidence beyond the studied durations is limited.
- The 2026 meta-analysis rated most trials as having some risk-of-bias concerns, with one large preregistered double-blind trial at low risk.
The two-year trial, up close: 237 women, one honest non-result
The largest creatine trial in postmenopausal women ran for two years (Chilibeck et al., published in Medicine & Science in Sports & Exercise): 237 women took daily creatine at 0.14 g per kg of body weight alongside strength training three times a week and daily walking. The headline finding was a non-result: creatine had no effect on bone mineral density. Saying so plainly is what separates evidence from marketing.
But the secondary outcomes told a richer story. Creatine improved walking time over 80 meters (a real functional measure, not a lab number), and in a subanalysis of valid completers it enhanced lean tissue mass versus placebo. The researchers also found that creatine maintained certain bone geometric properties at the femoral neck, such as section modulus and buckling ratio, which predict bending strength and fracture resistance, even without changing density itself. It was well tolerated with low adverse-event rates.
An earlier 12-month study paired about 0.1 g per kg of body weight a day with three-times-weekly resistance training and found a smaller decline in femoral-neck bone density with creatine (1.2 percent loss) than with placebo (3.9 percent loss). The honest synthesis: bone density evidence is mixed and mostly small-scale, while muscle, lean mass, and functional outcomes look consistently positive. Nobody has shown that creatine prevents fractures, and anyone claiming otherwise is out ahead of the evidence.
Where this evidence is weakest
Many menopause studies combine creatine with exercise, which means the evidence speaks most clearly to the combination, not to creatine alone. Some of the most interesting outcomes are secondary rather than primary endpoints, and secondary endpoints always deserve more caution. Trial adherence also matters, particularly across studies that run for years. None of this invalidates the findings. It defines their borders, which is what good evidence is supposed to do.
Next: Get your personal dose number from the calculator, then pair it with the first-month routine.
Common questions
Does creatine help with menopause muscle loss?
In postmenopausal women, the most consistent findings are modest lean-mass and strength gains, especially when you pair creatine with resistance training. Pooled results: lean mass +0.37 kg and leg-press strength +7.5 kg versus placebo.
Does creatine improve bone density in menopause?
The 2026 meta-analysis found no overall improvement in bone mineral density with creatine. Some geometric bone measures were better preserved. That's a different outcome. Fracture risk hasn't been established directly.
What creatine dose did the menopause studies use?
The gains showed up in trials using at least 5 g a day with resistance training. Trials using 3 g a day or less, without resistance training, didn't show a measurable benefit. That's a subgroup observation, not a personal prescription.
Memory and brain fog sit in creatine for the brain.
Sources
- Naddafha S, et al. 2026. Creatine monohydrate for lean mass, strength, and bone density in postmenopausal women: systematic review and meta-analysis.
- Seven RCTs, 608 randomized participants, 12 to 104 weeks. Used for pooled lean mass, leg-press strength, BMD, subgroup, safety, and bias findings.
- Chilibeck PD, et al. 2015. Effects of Creatine and Resistance Training on Bone Health in Postmenopausal Women.
- 12 months, creatine 0.1 g/kg/day plus resistance training. Used for femoral-neck BMD loss and femoral-shaft geometry.
- Chilibeck PD, et al. 2023. A 2-yr Randomized Controlled Trial on Creatine Supplementation during Exercise for Postmenopausal Bone Health.
- 237 randomized postmenopausal women, creatine 0.14 g/kg/day plus exercise. Used for null BMD results, geometry, walking time, and lean-tissue subanalysis.
Editorial note: This page is informational and does not provide personalized medical advice. Study findings describe groups, not guarantees for individuals. If you have a medical condition, take prescription medication, are pregnant, or have symptoms that concern you, discuss supplement use with a qualified clinician.